Tagged with pharmaceuticals,

Pharma 2016 has been a great year for PharmaBoardroom, with interviews from global CEOs and ministers, groundbreaking country reports on some of the world’s key pharma markets, and insightful articles which get to the heart of the sector’s key issues. Stay tuned in 2017 for more of the same! INTERVIEWS OF…

Switzerland Nasri Nahas, CEO of Biopôle in Switzerland, discusses his motivations for joining the biotech, and his mission to re-position the organization as a life sciences ecosystem bringing together academia, business, and research. What motivated you to join Biopôle in October 2015? I began my career as a molecular biologist in France…

Ireland Gearóid McDermott, director of Amneal Pharmaceuticals’ first site in Ireland down in Cashel, Co. Tipperary, outlines the exciting progress they have made in the past 14 months, the strategic role of the site as Amneal’s first manufacturing facility for inhalation products as Amneal enters the high-value generics space, and his…

Greece With extensive experience in the field of health economics, IOBE’s Head of the Health Economics Observatory, Thanos Athanasiadis, discusses the background of the organization, the state of the pharmaceutical market in Greece, and the existing challenges and opportunities in the country. To begin, could you please give an overview of…

Taiwan Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have allowed PharmaEngine to become the first Taiwan-based company to receive FDA approval for a locally-developed oncology treatment, as well as…

Switzerland Switzerland may have a world class healthcare system, but small adjustments are needed to ensure incentives for payer and providers are properly aligned with the patient’s ultimate quality and value of care. Dr. Cassis, could you please introduce yourself, with reference to your experience and current responsibilities in the realm…

Switzerland Advances in delivery technology and manufacturing costs have driven a surge of activity in peptide drug development, says Thomas Früh, CEO of Bachem –  the largest and most advanced peptide drug CMO in the world. Peptide therapeutics are a hot topic in the pharma industry today – what’s the story…

Singapore In an exclusive interview, Zuellig Pharma CEO John Davison provides insight into the new Zuellig Health Solutions unit that is providing strategic, topline-focused services in order to support Pharma companies in the region. He highlights the challenges the industry faces in penetrating the market and how Zuellig Pharma is closing…

Switzerland Outsourcing of API synthesis has stabilized in the decade since Rohner Chem entered the pharma sector in earnest, and according to CEO Daniel Pedrett the company has reached a position where it is faster, more agile and more experienced than the internal supply organizations of many mid-sized innovators. You were…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…

Slovakia The basics on the country of Slovakia: name, date of independence, geography, population, currency, language, and capital. Slovakia is well integrated into the international community, with membership of the majority of large transnational institutions. Slovakia is located at the heart of Europe, within a short flight of almost every other…

Switzerland With over 50 years of history in Switzerland, Zambon operates in Canton Ticino one of Zambon’s two major global production centers. Swiss Market  Manager Giampiero Roncoroni discusses the unique features of the Swiss market, and how a particular focus on the OTC/OTX market has been a key factor of success…